RT Journal Article
SR Electronic
T1 Genomic surveillance reveals the emergence of SARS-CoV-2 Lineage A from Islamabad Pakistan
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.24.21268367
DO 10.1101/2021.12.24.21268367
A1 Umair, Massab
A1 Ikram, Aamer
A1 Rehman, Zaira
A1 Haider, Syed Adnan
A1 Badar, Nazish
A1 Ammar, Muhammad
A1 Ali, Qasim
A1 Ahad, Abdul
A1 Suleman, Rana
A1 Salman, Muhammad
YR 2021
UL http://medrxiv.org/content/early/2021/12/25/2021.12.24.21268367.abstract
AB The lineage A of SARS-CoV-2 has been around the world since the start of the pandemic. In Pakistan the last case of lineage A was reported in April, 2021 since then no case has been reported. In November, 2021 during routine genomic surveillance at National Institute of Health we have found 07 cases of lineage A from Islamabad, Pakistan. The study reports two novel deletions in the spike glycoprotein. One 09 amino acid deletion (68-76 a.a) is found in the S1 subunit while another 10 amino acid deletion (679-688 a.a) observed at the junction of S1/S2 referred as furin cleavage site. The removal of furin cleavage site may result in impaired virus replication thus decreasing its pathogenesis. The actual impact of these two deletions on the virus replication and disease dynamics needs to be studied in detail. Moreover, the enhanced genomic surveillance will be required to track the spread of this lineage in other parts of the country.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Study was approved by Institutional Review Board of National Institute of Health.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the sequences generated in the current study are submitted to the GISAID that are available at https://www.gisaid.org/login/ under the accession numbers: EPI_ISL_7542800-EPI_ISL_7542804, EPI_ISL_7571414-EPI_ISL_7571415.